Seek emergency medical care (call 911) if experiencing: Seizure activity Convulsions, loss of consciousness, uncontrolled shaking, or post-event confusion Severe hypoglycemia symptoms Extreme confusion, loss of consciousness, inability to swallow, or seizure in a patient with diabetes Signs of severe dehydration Inability to urinate, extreme dizziness, rapid heartbeat, or altered mental status Severe abdominal pain Particularly if radiating to the back, which may indicate pancreatitis Allergic reactions Difficulty breathing, throat swelling, or widespread rash Contact your healthcare provider within 24 hours for: Persistent vomiting preventing medication or fluid intake for more than 24 hours, signs of dehydration (decreased urination, persistent dizziness), unexplained neurological symptoms (numbness, tingling, vision changes, severe headache), symptoms of hypoglycemia occurring frequently despite medication adjustments, or severe gastrointestinal symptoms not improving with standard management
36,37 Bimagrumab was tested in a double-blind, placebo-controlled, 48-week, phase 2 randomized clinical trial 38 in adults with type 2 diabetes and BMI 2840 kg/m 2
Although the LEADER was not initially designed to assess acute gallbladder or biliary disease, the results demonstrate an increased risk of gallbladder complications across the four categories in the liraglutide group compared with placebo
Bras stretch in the wash, and after many washes, they may no longer fit according to the size on the label
The results are expressed as the mean standard deviation (SD)
